OxThera AB
556681-5667ActiveDeveloping novel biotherapies for rare kidney diseases like Primary Hyperoxaluria.
Biopharmaceutical Companyoxthera.com
Översikt
- 0
- Anställda
- ≤1t SEK
- Omsättning
- 2005
- Grundat
Nyckelbeslutsfattare
Jonas Brambeck
Deputy Director of the Board
John Goldie
Chairman
Mats-Olof Wallin
Chief Financial Officer
Elisabeth Lindner
Chief Operating Officer
Beskrivning
OxThera AB is a privately-held biopharmaceutical company dedicated to developing novel treatment options for rare kidney diseases, primarily Primary Hyperoxaluria (PH). Their core mission is to improve the quality of life and extend the life expectancy of patients suffering from this devastating ult...